Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults.
Tom D Wilsdon, Ivanka Hendrix, Tilenka R J Thynne...
https://pubmed.ncbi.nlm.nih.gov/28220380Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID06858384
From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study
Led by RAK Medical and Health Sciences University · Updated on 2025-03-12
479
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether a pharmacist-led educational program can reduce the inappropriate use of proton pump inhibitors (PPIs) among adults aged 18 years and older with potentially unnecessary PPI prescriptions in Ras Al Khaimah. The study aims to see if this intervention can lower PPI use, improve patients' quality of life, and reduce healthcare costs by comparing the intervention group to those receiving usual care. The study is interventional and involves education for both patients and physicians to promote evidence-based deprescribing practices. The study has two groups: one receives a pharmacist-led educational intervention including brochures, videos, decision aids, and deprescribing algorithms aimed at encouraging appropriate PPI use. The other group continues with standard care without any pharmacist intervention during the six-month period. Physicians in the intervention group also receive educational materials and guidance to support deprescribing. After six months, educational materials will be offered to the control group. Participants will be followed for six months to track changes in PPI use, symptoms related to gastroesophageal reflux disease, quality of life, medication counts, potential adverse effects, attitudes toward deprescribing, and healthcare costs. Assessments include questionnaires such as the Gastroesophageal Reflux Disease Impact Scale and EuroQol 5-Dimension 5-Level survey. Researchers will monitor if patients stop or reduce PPI doses and evaluate cost-effectiveness and quality-adjusted life years gained over the study period.
CONDITIONS
Brief Title
RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Physicians prescribing PPIs in outpatient departments at the study sites
- Physicians who have patients with potentially inappropriate PPI prescriptions
- Patients aged 18 years or older
- Patients presenting to outpatient departments of the study sites
- Patients with prescriptions for potentially inappropriate PPIs
- Patients whose treating physicians are included in the study
You will not qualify if you...
- Physicians participating in any other prescribing trial
- Patients unable to give informed consent as judged by their physicians
- Patients with definitive indications for PPI use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Intervention Period
Duration - 6 months
Participants receive either a pharmacist-led educational intervention focused on appropriate use and deprescribing of proton pump inhibitors, or continue with their usual care without additional intervention.
Visits as per routine clinical care; educational materials provided to intervention arm
Trial Site Locations
Total: 1 location
1
Ibrahim Bin Hamad Obaidullah Hospital
Ras al-Khaimah, United Arab Emirates
Actively Recruiting
Loading map...
Research Team
S
Syed Arman Rabbani
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Deprescribing Proton Pump Inhibitors in an Academic, Primary Care Clinic: Quality Improvement Project.
Naren Nallapeta, Jessica L Reynolds, Smita Bakhai
https://pubmed.ncbi.nlm.nih.gov/32091449Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial.
N Krol, M Wensing, F Haaijer-Ruskamp...
https://pubmed.ncbi.nlm.nih.gov/15080853Deprescribing Inappropriate Proton Pump Inhibitors in a Family Medicine Residency Practice Office.
Andrew Lai, Amy Odom, Steven E Roskos...
https://pubmed.ncbi.nlm.nih.gov/34841218Use of proton pump inhibitors among older Australians: national quality improvement programmes have led to sustained practice change.
Nicole L Pratt, Lisa M Kalisch Ellett, Janet K Sluggett...
https://pubmed.ncbi.nlm.nih.gov/27920248Sustained effectiveness of a multifaceted intervention to reduce potentially inappropriate prescribing in older patients in primary care (OPTI-SCRIPT study).
Barbara Clyne, Susan M Smith, Carmel M Hughes...
https://pubmed.ncbi.nlm.nih.gov/27255504Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors.
Emily Reeve, Jane M Andrews, Michael D Wiese...
https://pubmed.ncbi.nlm.nih.gov/25385826Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.
Barbara Farrell, Kevin Pottie, Wade Thompson...
https://pubmed.ncbi.nlm.nih.gov/28500192What next for the Australian Atlas of Healthcare Variation series? Focusing the system on appropriate and sustainable health care.
Gillian Giles, Heather Buchan, Carolyn Hullick...
https://pubmed.ncbi.nlm.nih.gov/39695003We have had a gutful: The need for deprescribing proton pump inhibitors.
M Naunton, G M Peterson, L S Deeks...
https://pubmed.ncbi.nlm.nih.gov/28895169